Portugal: Recipharm bolsters biologics offering with acquisition of GenIbet

Global contract development and manufacturing organisation (CDMO), Recipharm, has acquired Portuguese CDMO, GenIbet. GenIbet specialises in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the biologics market, with a particular focus on drug substance manufacturing of…

You must be a HMI Subscriber to view this content.

Subscribe Now »